X
Story Stream
recent articles

Washington has a remarkable talent for finding healthcare villains. Drug companies get hauled before Congress. Insurers and pharmacy benefit managers get their turn in the dock. Hospitals? Not so much. Yet hospital care accounts for the largest share of national health spending. Why the free pass?

According to the Bureau of Labor Statistics, hospital service prices climbed roughly 281 percent from January 2000 through December 2025, against about 93 percent for consumer prices overall. The comparison deserves a careful look at the underlying series, but the disparity is striking. Where’s the congressional outrage?

Nobody needs reminding that hospitals save lives. They operate emergency rooms, train physicians and care for people at their most vulnerable. Some rural hospitals are barely hanging on. But recognizing their value does not mean accepting every bill they send. The financially distressed community hospital and the multibillion-dollar regional system are not interchangeable, and public policy should stop pretending they are.

A drug's list price can dominate a congressional hearing, even when rebates and discounts complicate the real number. Hospital charges, negotiated behind closed doors and often unintelligible to the patient, seldom provoke the same outrage. That is not a serious approach to healthcare affordability. It is selective indignation.

As I argued in Health Affairs Forefront, five years of federal hospital price transparency requirements have exposed a basic weakness in Washington's thinking: disclosure is not competition. A hospital can publish a mountain of pricing files and still leave patients unable to answer the only question they care about: What will this cost me? Transparency that cannot inform a decision is little more than a compliance exercise.

Try buying a car without knowing the price until after you drive it home. That is roughly how hospital billing works for too many patients. Insurers negotiate different rates, deductibles complicate the math, and the final bill arrives when the care is already over. Emergency care will never resemble ordinary shopping. But for scheduled services, usable, comparable prices should not be an exotic idea.

Hospital consolidation has only made matters worse. When hospitals merge into dominant regional systems, insurers lose leverage and patients lose options. Studies have associated concentrated hospital markets with higher commercial prices, without consistent gains in quality. Employers pay more for coverage, workers absorb more of the cost, and families wonder why their premiums keep climbing. Market power has a price, and patients ultimately pay it.

Nonprofit hospitals deserve a closer look, too. Tax exemption is not a decorative label. It is a public benefit granted in expectation of a public return. Some nonprofit systems have sprawling real estate portfolios, major investment holdings and executive pay packages that would fit comfortably in the Fortune 500. Nobody begrudges a hospital financial success. Taxpayers are entitled to ask what they're getting in return.

That question becomes urgent when a tax-exempt institution pursues patients over unpaid bills, provides limited charity care or uses its negotiating muscle to demand higher rates. A 2021 Trilliant Health analysis found that 40 nonprofit health systems would have qualified for a Fortune 500-style ranking based on revenue. Size alone proves nothing improper. It does, however, make the old image of the modest neighborhood charity rather difficult to sustain.

The remedy is not to slap price controls on every hospital in America. Congress should demand transparency that ordinary people can use, and regulators should pay closer attention to mergers and contracting practices that choke off competition. Tax-exempt systems should have to demonstrate community benefits worthy of the tax advantages they receive. Hardly radical. Just basic accountability for institutions receiving substantial public benefits.

Nor should Washington treat a rural hospital struggling to keep its emergency department open as though it were a metropolitan system using its market position to command higher rates. Good regulation distinguishes between the two. That is regulatory nimbleness, not regulatory weakness.

For years, politicians have found it easier to attack the price of a pill than to untangle hospital contracts, insurance negotiations and tax subsidies. But patients do not experience healthcare costs in separate political categories. They experience them in premiums, deductibles and bills they cannot predict. If Congress is serious about affordability, it should follow the money wherever it leads, including through the hospital doors. Hospitals deserve respect for the lives they save – not a pass on the prices they charge.

Peter J. Pitts, a former FDA Associate Commissioner, is President of the Center for Medicine in the Public Interest

Comment
Show comments Hide Comments